ASP Isotopes Inc. (ASPI) Stock Analysis and Metrics

ASP Isotopes

NASDAQ: ASPI

$3.88 ▼ -0.16 (-4.08%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap488.84 Mn

P/E-3.32

P/S18.15

Div. Yield0.00

ROIC (Qtr)-0.02

Total Debt (Qtr)111.59 Mn

Revenue Growth (1y) (Qtr)279.31

Add ratio to table…

About

ASP Isotopes Inc. is an advanced materials company focused on developing and commercializing isotope enrichment technologies for nuclear medicine semiconductors and nuclear energy. The company’s core assets are its proprietary Aerodynamic Separation Process ASP and Quantum Enrichment QE platforms which enable production of enriched isotopes such as carbon 14 silicon 28 and ytterbium 176. In addition ASP Isotopes owns Renergen South Africa’s leading onshore natural gas explorer and the first integrated producer of liquid helium and liquefied natural gas LNG. Through subsidiaries PET Labs and East Coast Nuclear Pharmacy it participates in downstream radiopharmacy and through its ownership of Skyline it provides construction services in Hong Kong. The firm also pursues a nuclear fuels business via its subsidiary Quantum Leap Energy QLE to produce high assay low enriched uranium HALEU and lithium 6 for advanced reactors.

ASP Isotopes generates revenue primarily from the sale of enriched isotopes helium and LNG as well as from construction contracts and licensing royalties. The company has secured tolling and purchase agreements for its future isotope output including a multi year take or pay contract with a Canadian customer for carbon 14 and purchase orders from a U S semiconductor company and a global industrial gas company for silicon 28. Renergen contributes revenue through domestic LNG sales in South Africa and planned exports of high purity helium to global markets facing supply shortages. Skyline’s construction arm earns fees from civil engineering projects such as road and drainage works in Hong Kong. ASP Isotopes also receives a perpetual royalty equal to 10 % of future QLE revenues under a license agreement that grants QLE the right to use ASP and QE technologies for uranium and lithium 6 enrichment.

The company operates through three reportable segments nuclear fuels specialist isotopes and related services and construction services.

• Nuclear Fuels: This segment is focused on research and development of technologies and methods to produce high assay low enriched uranium HALEU and lithium 6 for advanced nuclear reactors including small modular reactors. It encompasses the activities of Quantum Leap Energy its partnerships with TerraPower and NECSA and the pursuit of uranium enrichment projects in South Africa the United States and the United Kingdom.

• Specialist Isotopes and Related Services: This segment concentrates on the development and commercialization of high value low volume isotopes such as carbon 14 silicon 28 and ytterbium 176 for markets including pharmaceuticals agrochemicals nuclear medical imaging and semiconductors. It includes the ASP and QE enrichment facilities in Pretoria the downstream radiopharmacy operations of PET Labs and East Coast Nuclear Pharmacy and related technical services.

• Construction Services: This segment provides public civil engineering works in Hong Kong chiefly road and drainage projects through Skyline’s wholly owned subsidiaries Kin Chiu Engineering Limited and Kin Chiu Development Company Limited. Activities involve site clearance concrete installation excavation fill compaction and landscaping.

ASP Isotopes holds a differentiated position in the isotope enrichment industry due to its low cost modular ASP and QE technologies which enable efficient separation of light isotopes where traditional centrifuges are less effective. The company faces competition from established biotech and nuclear medicine firms for medical isotopes and from other enrichment enterprises for uranium but it benefits from proprietary know‑how lower capital expenditures and the ability to site facilities near end users. In the helium and LNG markets Renergen enjoys a near monopoly as South Africa’s sole domestic LNG producer and exploits a helium concentration above 3 % far exceeding typical global averages giving it a cost advantage over overseas suppliers. In construction Skyline competes with local contractors but gains access to projects through its parent’s relationships and its status as an approved main contractor.

The company’s customer base includes a Canadian off taker for carbon 14 a U S semiconductor company and a global industrial gas company for silicon 28 and TerraPower as a prospective buyer of HALEU. Renergen sells LNG to domestic South African utilities and industrial users and intends to export helium to international customers in the semiconductor aerospace and medical imaging sectors. Skyline serves property developers government agencies and infrastructure firms in Hong Kong that require civil engineering works. Additionally ASP Isotopes supplies radiopharmaceuticals to hospitals and clinics through its PET Labs and East Coast Nuclear Pharmacy subsidiaries.

Investment Thesis

▲ Bull case

ASP Isotopes operates in a strategically critical niche with the production and enrichment of isotopes, particularly High Assay Low-Enriched Uranium (HALEU), which is essential for next-generation nuclear reactors and has limited domestic supply chains in the United States, creating a potential first-mover advantage if the company can successfully scale its technology despite current setbacks, as the U.S. government has prioritized securing HALEU supply through initiatives like the Department of Energy’s HALEU Availability Program, which could provide substantial funding or off-take agreements to de-risk commercialization efforts. The company’s focus on advanced materials and isotope separation technology may have applications beyond nuclear fuel, including medical isotopes for diagnostics and treatment, industrial sensors, and quantum computing components, suggesting potential diversification pathways that management has not emphasized but could unlock additional revenue streams if the core platform proves viable, reducing reliance on a single market and increasing long-term resilience. Despite negative reports and litigation, the persistence of investor interest and ongoing legal scrutiny implies that the underlying technology may have credible foundations worth defending, as law firms typically pursue cases only when there is evidence of material misrepresentation rather than baseless claims, indicating that the company’s disclosures, while possibly flawed, may still reflect genuine progress that has been understated or mischaracterized in public critiques. The repeated initiation of investigations by reputable law firms such as Halper Sadeh LLC and Kahn Swick & Foti LLC could indirectly pressure management to improve transparency and operational discipline, potentially leading to stronger corporate governance, more realistic timelines, and better communication with stakeholders—changes that, if implemented, might restore investor confidence and allow the company to execute its vision more effectively over time. As a development-stage company, ASP Isotopes may still be in the early phases of technological validation, and the absence of recent earnings calls could reflect a deliberate focus on R&D milestones rather than financial reporting, suggesting that meaningful technical progress—such as successful isotope separation benchmarks or pilot plant operations—might be occurring quietly without public disclosure, positioning the company for a potential inflection point once key thresholds are met.

ASP Isotopes operates in a strategically critical niche with the production and enrichment of isotopes, particularly High Assay Low-Enriched Uranium (HALEU), which is essential for next-generation nuclear reactors and has limited domestic supply chains in the United States, creating a potential first-mover advantage if the company can successfully scale its technology despite current setbacks, as the U.S. government has prioritized securing HALEU supply through initiatives like the Department of Energy’s HALEU Availability Program, which could provide substantial funding or off-take agreements to de-risk commercialization efforts. The company’s focus on advanced materials and isotope separation technology may have applications beyond nuclear fuel, including medical isotopes for diagnostics and treatment, industrial sensors, and quantum computing components, suggesting potential diversification pathways that management has not emphasized but could unlock additional revenue streams if the core platform proves viable, reducing reliance on a single market and increasing long-term resilience. Despite negative reports and litigation, the persistence of investor interest and ongoing legal scrutiny implies that the underlying technology may have credible foundations worth defending, as law firms typically pursue cases only when there is evidence of material misrepresentation rather than baseless claims, indicating that the company’s disclosures, while possibly flawed, may still reflect genuine progress that has been understated or mischaracterized in public critiques. The repeated initiation of investigations by reputable law firms such as Halper Sadeh LLC and Kahn Swick & Foti LLC could indirectly pressure management to improve transparency and operational discipline, potentially leading to stronger corporate governance, more realistic timelines, and better communication with stakeholders—changes that, if implemented, might restore investor confidence and allow the company to execute its vision more effectively over time. As a development-stage company, ASP Isotopes may still be in the early phases of technological validation, and the absence of recent earnings calls could reflect a deliberate focus on R&D milestones rather than financial reporting, suggesting that meaningful technical progress—such as successful isotope separation benchmarks or pilot plant operations—might be occurring quietly without public disclosure, positioning the company for a potential inflection point once key thresholds are met.

▼ Bear case

ASP Isotopes faces severe credibility issues following allegations from Fuzzy Panda Research that the company misrepresented the viability of its nuclear fuel technologies, including claims it never tested its quantum enrichment (QE) process on uranium, used outdated diagrams, and provided delusional timelines and cost estimates for HALEU facility construction, which directly undermine investor trust and suggest a pattern of overpromising on technical capabilities that may not be substantiated by actual progress. The denial of the company’s motion to dismiss in the securities class action lawsuit indicates that the court found sufficient merit in the allegations of failing to disclose material information, meaning the litigation is likely to proceed to discovery and potentially trial, exposing the company to significant legal costs, potential damages, and reputational harm that could distract management and drain financial resources at a critical stage of development. Repeated investigations by multiple investor rights law firms—Halper Sadeh LLC and Kahn Swick & Foti LLC—signal deepening concerns among shareholders about possible fiduciary breaches, including potential misappropriation of funds, inadequate oversight, or misleading disclosures, which, if substantiated, could lead to governance reforms, financial restitution, or even executive accountability, further eroding confidence in leadership. As a development-stage company with no meaningful revenue generation disclosed in the provided materials, ASP Isotopes remains heavily dependent on future success in a highly capital-intensive and technologically uncertain field, where failure to deliver on promised milestones could result in continued dilution, loss of investor support, and an inability to secure the partnerships or funding necessary to scale operations. The nuclear fuel enrichment sector is subject to stringent regulatory oversight, long development cycles, and high barriers to entry, meaning that even if the technology is viable, ASP Isotopes may face insurmountable challenges in obtaining necessary licenses, competing with established players, or meeting the purity and production standards required for commercial HALEU sales, making the path to profitability exceptionally long and uncertain.

ASP Isotopes faces severe credibility issues following allegations from Fuzzy Panda Research that the company misrepresented the viability of its nuclear fuel technologies, including claims it never tested its quantum enrichment (QE) process on uranium, used outdated diagrams, and provided delusional timelines and cost estimates for HALEU facility construction, which directly undermine investor trust and suggest a pattern of overpromising on technical capabilities that may not be substantiated by actual progress. The denial of the company’s motion to dismiss in the securities class action lawsuit indicates that the court found sufficient merit in the allegations of failing to disclose material information, meaning the litigation is likely to proceed to discovery and potentially trial, exposing the company to significant legal costs, potential damages, and reputational harm that could distract management and drain financial resources at a critical stage of development. Repeated investigations by multiple investor rights law firms—Halper Sadeh LLC and Kahn Swick & Foti LLC—signal deepening concerns among shareholders about possible fiduciary breaches, including potential misappropriation of funds, inadequate oversight, or misleading disclosures, which, if substantiated, could lead to governance reforms, financial restitution, or even executive accountability, further eroding confidence in leadership. As a development-stage company with no meaningful revenue generation disclosed in the provided materials, ASP Isotopes remains heavily dependent on future success in a highly capital-intensive and technologically uncertain field, where failure to deliver on promised milestones could result in continued dilution, loss of investor support, and an inability to secure the partnerships or funding necessary to scale operations. The nuclear fuel enrichment sector is subject to stringent regulatory oversight, long development cycles, and high barriers to entry, meaning that even if the technology is viable, ASP Isotopes may face insurmountable challenges in obtaining necessary licenses, competing with established players, or meeting the purity and production standards required for commercial HALEU sales, making the path to profitability exceptionally long and uncertain.

Peer Comparison

Companies in the Chemicals

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	CE	Celanese Corp	5.19 Bn	-305.45	0.55	12.55 Bn
2	MEOH	Methanex Corp	4.49 Bn	-83.59	1.22	2.71 Bn
3	OLN	OLIN Corp	2.69 Bn	-14.55	0.40	3.00 Bn
4	BAK	Braskem Sa	1.98 Bn	-8.33	0.15	9.61 Bn
5	REX	REX AMERICAN RESOURCES Corp	1.49 Bn	17.71	2.29	-
6	GPRE	Green Plains Inc.	1.18 Bn	90.00	0.61	0.46 Bn
7	TROX	Tronox Holdings plc	1.02 Bn	-2.18	0.35	3.16 Bn
8	LXU	Lsb Industries, Inc.	0.88 Bn	18.77	1.37	0.45 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password